Literature DB >> 21685371

MicroRNA29a regulates the expression of the nuclear oncogene Ski.

Sabine Teichler1, Thomas Illmer, Josephine Roemhild, Dmitriy Ovcharenko, Thorsten Stiewe, Andreas Neubauer.   

Abstract

MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate growth and differentiation. miRNAs are frequently located at cancer-specific fragile sites in the human genome, such as chromosome 7q. The nuclear oncogene SKI is up-regulated in acute myeloid leukemia (AML) with -7/del7q. Here we asked whether loss of miRNAs on chromosome 7q may explain this up-regulation. miR-29a expression was found to be down-regulated in AML with -7/del7q. Forced expression of miR-29a down-regulated Ski and its target gene, Nr-CAM, whereas miR-29a inhibition induced Ski expression. Luciferase assays validated a functional binding site for miR-29a in the 3' untranslated region of SKI. Finally, in samples of AML patients, we observed an inverse correlation of Ski and miR-29a expression, respectively. In conclusion, up-regulation of Ski in AML with -7/del7q is caused by loss of miR-29a. miR-29a may therefore function as an important tumor suppressor in AML by restraining expression of the SKI oncogene.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685371     DOI: 10.1182/blood-2010-09-306258

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Making a long story short: noncoding RNAs and chromosome change.

Authors:  J D Brown; S E Mitchell; R J O'Neill
Journal:  Heredity (Edinb)       Date:  2011-11-09       Impact factor: 3.821

2.  Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia.

Authors:  Xishan Zhu; Ziying Lin; Jing Du; Xu Zhou; Lawei Yang; Gang Liu
Journal:  Mol Cell Biochem       Date:  2014-01-03       Impact factor: 3.396

Review 3.  MicroRNA-29 in the adaptive immune system: setting the threshold.

Authors:  Adrian Liston; Aikaterini S Papadopoulou; Dina Danso-Abeam; James Dooley
Journal:  Cell Mol Life Sci       Date:  2012-09-13       Impact factor: 9.261

4.  MiR-29a modulates the angiogenic properties of human endothelial cells.

Authors:  Zeran Yang; Lingjiao Wu; Xiuming Zhu; Jie Xu; Rong Jin; Guohong Li; Fusheng Wu
Journal:  Biochem Biophys Res Commun       Date:  2013-03-28       Impact factor: 3.575

5.  MicroRNA target prediction: theory and practice.

Authors:  Mathias Wagner; Benjamin Vicinus; Vilma Oliveira Frick; Michael Auchtor; Claudia Rubie; Pascal Jeanmonod; Tereza A Richards; Roland Linder; Frank Weichert
Journal:  Mol Genet Genomics       Date:  2014-06-18       Impact factor: 3.291

6.  The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.

Authors:  Z Xishan; L Xianjun; L Ziying; C Guangxin; L Gang
Journal:  Cancer Gene Ther       Date:  2014-09-12       Impact factor: 5.987

7.  Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.

Authors:  X Zhu; H Zhao; Z Lin; G Zhang
Journal:  Cancer Gene Ther       Date:  2015-10-23       Impact factor: 5.987

8.  Recurrent isochromosome 21 and multiple abnormalities in a patient suspected of having acute myeloid leukemia with eosinophilic differentiation -- a rare case from South India.

Authors:  Sangeetha Vijay; Santhi Sarojam; Sureshkumar Raveendran; Vani Syamala; Sreeja Leelakumari; Geetha Narayanan; Sreedharan Hariharan
Journal:  Chin J Cancer       Date:  2011-12-16

9.  The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells.

Authors:  Christina Halsey; Marie Docherty; Mhairi McNeill; Derek Gilchrist; Michelle Le Brocq; Brenda Gibson; Gerard Graham
Journal:  J Hematol Oncol       Date:  2012-08-01       Impact factor: 17.388

10.  Identification of sensitive serum microRNA biomarkers for radiation biodosimetry.

Authors:  Naduparambil Korah Jacob; James V Cooley; Tamara N Yee; Jidhin Jacob; Hansjuerg Alder; Priyankara Wickramasinghe; Kirsteen H Maclean; Arnab Chakravarti
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.